Johnson & Johnson (JNJ) Buy, Sell or Hold

Johnson & Johnson (JNJ)

266.35

-0.73 (0.27%)

as of Sep 10, 2026, 8:00:00 pm Market Open.

697 watching

DON'T BUY

Has done better than the other US pharmaceuticals. The sector has not done well. This will be a tough hold because generics will give a lot of competition.

Wealthica Track your Stocks in your Watch List

BUY

One of the best consumer product companies with a big medical exposure. Recent study indicated stents are no more effective than drugs, so the stock dropped. A great hedge against a weaker US economy.

TOP PICK

Feels you can get a double-digit return out of this one. Good opportunities for earnings improvement. Good price.

BUY

He likes it for the health care products, more than for the pharmaceutical and medical devices. The stent business is under serious question right now. Trades at a very reasonable PE.

DON'T BUY

Looking a lot better than it did, but still overvalued. His model price is $56.90. Negative 8% differential.

BUY

Likes this a lot. A multinational which pays a dividend.

BUY

A great company and well run. While diversified with pharmaceuticals and consumer products. Throws off lots of free cash flow.

HOLD

This is a company that will have lower return, but more stable. There is a good opportunity for a return in the future.

DON'T BUY

Model price of $57.07, a negative 14% differential. Typical of consumer staples where the market rotated into heavily this year.

BUY

Household products form a base for this company, and he sees the pharmaceuticals as an add-on. Excellent earnings.

BUY

Looks interesting. More consumer products than some of the other large pharmas.

DON'T BUY

His model price is $53.22 which is a negative 17% differential. If you want a great company in your portfolio for 20/30 years, this may be the one, or if you're trying to beat the S&P 500.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

DON'T BUY

The “gold standard” in the healthcare industry. The problem is when you look at earnings growth in healthcare it is the lowest and has the lowest expectations. Would avoid this sector.

BUY

A hybrid. Part pharmaceutical/medical devices and part consumer products. Just in the process of buying Pfizer's (PFE-N) consumers product division. Has had fabulous management. Great growth in earnings.

Showing 541 to 555 of 628 entries

Most Recent Experts

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Gordon Reid

GoodReid Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)